Abbreviations
2-AG, 2-arachidonoyl-glycerol; 5-HT1A, serotoninergic
receptors of the 5-HT1A type; AEA, anandamide; BCP,
β-caryophyllene; CB1, cannabinoid receptor 1; CB2, cannabinoid receptor
2; CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiolic acid;
CBDV, cannabidivarin; CBG, canabigerol; CNS, Central nervous system; D;
DAGLα, diacylglycerol lipase α; DAGL, sn-1-diacylglycerol lipase; DAGLβ,
diacylglycerol lipase β; EAE, Experimental autoimmune encephalomyelitis;
ERK, protein extracellular signal-regulated kinase; ES, endocannabinoid
system; FAAH, fatty acid amide hydrolase; FDA, Food and Drug
Administration; FoxP3, Forkhead box P3; GABAA,
γ-Aminobutyric acid type A; GPCRs, orphan G protein-coupled receptors;
GPR118; G protein-coupled receptor 118; GPR119; G protein-coupled
receptor 119; GPR18; G protein-coupled receptor 18; GPR55, G
protein-coupled receptor 55; IL-10, Interleukin-10; IL-17,
Interleukin-17; IL-1β, Interleukin 1 beta; IL-4, Interleukin-4; IL-6,
Interleukin-6; INF-γ, Interferon gamma; MAGL, monoacylglycerol lipase;
miRNA, MicroRNA; MS, Multiple sclerosis; NAPE-PLD, N-acyl-phosphatidyl
ethanolamine-specific phospholipase; OEA, N-oleoylethanolamine; PEA,
N-palmitoylethanolamine; PPARα, peroxisome proliferator-actived receptor
α; PPARγ, peroxisome proliferator-actived receptor γ; STAT5b, signal
transducer and activator of transcription 5B; TBX21; T-box transcription
factor 21; TGF-β, Transforming growth factor beta; THC,
Δ9 -tetrahidrocanabinol; THCA,
∆9-tetrahydrocannabinolic acid; THCV, ∆9-
tetrahydrocannabivarin; TNF-α, Tumor necrosis factor alpha; TRPM8,
transient receptor potential cation channel subfamily M (melastatin)
member 8; TRPV1, transient receptor potential vanilloid 1.